Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Presentation TCT 2024

TCT 230: Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk: A Post-Hoc Analysis of the TWILIGHT Trial

Presenter: Mauro Gitto

October 27, 2024

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Presentation TCT 2023

Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-analysis of the TWILIGHT and TICO Randomized Trials

Presenter: Usman Baber

October 23, 2023

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

Caitlin E. Cox

November 06, 2021

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

Presentation TCT 2019

STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice?

Presenter: Aditya Kapoor

September 28, 2019

Presentation TCT 2019

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

Presenter: Pascal Vranckx

September 28, 2019

Presentation TCT 2019

COMPLETE Trial: Focus on STEMI and MVD

Presenter: Shamir Mehta

September 26, 2019

Presentation TCT 2019

Reconciling Adjudicated Data Within a Global Trial

Presenter: Marco Valgimigli

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Presenter: Roxana Mehran

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

Presentation TCT 2017

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Presenter: C. Michael Gibson, Stephan Windecker, Eric R. Bates

October 30, 2017

Presentation TCT 2016

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, C. Michael Gibson

October 30, 2016

Presentation TCT 2015

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran

October 11, 2015

Advertisement

TCT 230: Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk: A Post-Hoc Analysis of the TWILIGHT Trial

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-analysis of the TWILIGHT and TICO Randomized Trials

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice?

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

COMPLETE Trial: Focus on STEMI and MVD

Reconciling Adjudicated Data Within a Global Trial

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content